Merrimack Pharmaceuticals

$6.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell MACK and other stocks, options, ETFs, and crypto commission-free!

About MACK

Merrimack Pharmaceuticals, Inc. Common Stock, also called Merrimack Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Read More Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Employees
27
Headquarters
Cambridge, Massachusetts
Founded
1993
Market Cap
90.01M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
34.20K
High Today
$7.04
Low Today
$6.68
Open Price
$6.72
Volume
85.39K
52 Week High
$7.50
52 Week Low
$3.34

Collections

MACK News

BenzingaAug 16

Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting of Shareholders for October 17, 2019

10

MACK Earnings

-$1.33
-$0.98
-$0.62
-$0.27
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 6, Pre-Market

More MACK News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.